You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The partners have already identified cases in the US of the novel, highly transmissible SARS-CoV-2 variant that was first reported in the UK.
The firm's RT-PCR-based COVID-19 tests will be administered at fixed sites and by mobile units across the state.
Florida's largest county joins several major California counties in deploying Fulgent Genetics' PCR-based COVID-19 tests in a drive-through setting.
The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.
The California-based genetic testing firm said its new lab will be able to process 20,000 tests per day and will initially focus on COVID-19 testing.
Samples collected over time from more than 300 SARS-CoV-2-infected young adults pointed to prolonged viral shedding in symptom-free individuals.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner.
Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.
A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.